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Abstract
Background: The STTR treatment cascade provides a framework for research aimed at improving the delivery of
services, care and outcomes of PLWH. The development of effective approaches to increase HIV diagnoses and
engage PLWH in subsequent steps of the treatment cascade could lead to earlier and sustained ART treatment
resulting in viral suppression. There is an unmet need for research applying the treatment cascade to improve
outcomes for those with criminal justice involvement.
Methods: The Seek, Test, Treat, and Retain (STTR) criminal justice (CJ) cohort combines data from 11 studies across
the HIV treatment cascade that focused on persons involved in the criminal justice system, often but not exclusively
for reasons related to substance use. The studies were conducted in a variety of CJ settings and collected
information across 11 pre-selected domains: demographic characteristics, CJ involvement, HIV risk behaviors, HIV
and/or Hepatitis C infections, laboratory measures of CD4 T-cell count (CD4) and HIV RNA viral load (VL), mental
illness, health related quality of life (QoL), socioeconomic status, health care access, substance use, and social
support.
Results: The STTR CJ cohort includes data on 11,070 individuals with and without HIV infection who range in age
from 18 to 77 years, with a median age at baseline of 37 years. The cohort reflects racial, ethnic and gender
distributions in the U.S. CJ system, and 64% of participants are African-American, 12% are Hispanic and 83% are
men. Cohort members reported a wide range of HIV risk behaviors including history of injection drug use and,
among those who reported on pre-incarceration sexual behaviors, the prevalence of unprotected sexual intercourse
ranged across studies from 4% to 79%. Across all studies, 53% percent of the STTR CJ cohort reported recent
polysubstance use.
Conclusions: The STTR CJ cohort is comprised of participants from a wide range of CJ settings including jail,
prison, and community supervision who report considerable diversity in their characteristics and behavioral
practices. We have developed harmonized measures, where feasible, to improve the integration of these studies
together to answer questions that cannot otherwise be addressed.
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Background
STTR treatment cascade
The Seek, Test, Treat and Retain (STTR) treatment or
HIV care cascade is a challenging yet potentially benefi-
cial response to addressing HIV in an era of effective
treatments [1–3]. This approach requires reaching out
to at-risk individuals who have not been tested for HIV
recently (Seek), engaging them in HIV testing (Test), ini-
tiating persons living with HIV (PLWH) on antiretroviral
therapy (ART) and other treatment services (Treat), and
facilitating uninterrupted HIV care (Retain) [1, 2]. The
STTR treatment cascade provides a framework for re-
search aimed at improving the delivery of services, care
and outcomes of PLWH. There is substantial dropout
across each cascade step, and it has been estimated that
only ~19% of PLWH in the United States (US) are aware
of their HIV diagnosis, engaged in care, on ART, and
have an undetectable viral load (VL) [1], although more
recent numbers suggest improvements [4, 5]. The devel-
opment of effective approaches to increase HIV diagno-
ses and engage PLWH in subsequent steps of the
treatment cascade could lead to earlier and sustained
ART treatment resulting in viral suppression. Improve-
ments in the STTR treatment cascade have the potential
to benefit the health of PLWH and improve public
health by reducing HIV transmission [2].
The relevance of understanding the STTR treatment
cascade across all CJ settings
In the US, there are two main types of correctional facili-
ties—jails, that typically are administered by city or county
governments, and hold people awaiting trials or serving
shorter sentences (generally under two years), and prisons
that typically are administered by state and federal govern-
ments and hold people serving longer sentences or who
have had their parole or probation revoked. Community
supervision includes pretrial, probation and parole. Pretrial
refers to people awaiting trial before receiving a criminal
conviction or acquittal. Probation refers to adults who have
been placed on supervision in the community, typically
through local or state court systems; about half of individ-
uals on probation also serve a short jail sentence. Parole re-
fers to people who are released early from prison to serve
the remaining part of their sentence in the community [6].
The criminal histories of people in prison typically are more
serious, lengthy, and varied than individuals in jail or on
community supervision [7, 8].
Currently, >95% of incarcerated individuals will be re-
leased and re-enter society with nearly 80% being re-
leased to parole supervision [9]. About 1 in 35 adults in
the U.S. are under CJ supervision, and the number is ex-
pected to continue to increase [10]. This trend expands
opportunities for HIV prevention and treatment, espe-
cially in the public health realm [11]. Specifically, the
estimated HIV prevalence among individuals incarcerated
in the US prison system is 2-3 times higher than the gen-
eral population [12–16]. These statistics translate to one
in seven PLWH being incarcerated each year, a figure that
rises to one in five PLWH who are African-American or
Hispanic [17]. Although HIV testing rates in federal and
state prisons are generally high (71%), [18, 19] testing rates
in jails are not (19%) [18]. Because many CJ-involved indi-
viduals pass only through jail, it is likely that many who
are infected will not be offered HIV testing [18, 20]. These
individuals may not know their HIV status or their poten-
tial to transmit HIV [21]. Lack of testing among this
higher risk group, and early ART initiation for those who
are infected, is a lost opportunity to improve individual
and public health and decrease HIV transmission. Those
with HIV who return to the communities where they may
lack access to health care services, including screening
and early diagnosis, are likely to receive HIV treatment
only after the disease has progressed to advanced stages
[16, 22]. As such, the Centers for Disease Control and Pre-
vention (CDC) encourages more frequent HIV testing of
persons within the CJ system, particularly those with
drug-dependencies, because PLWH who learn their HIV
status are less likely to spread HIV and more likely to seek
medical treatment that can lower the potential for HIV
transmission and reduce HIV-associated morbidity and
mortality [23, 24]. Finally, while PLWH incarcerated in
prisons have access to care, including ART, maintaining
ART and other medical services is a significant challenge
for many re-entering the community following incarcer-
ation in prison [25] and engagement in the HIV care cas-
cade has been shown to decline substantially after release
[26]. Effective interventions are essential to link individuals
to appropriate post-incarceration care and enhance reten-
tion in HIV care. The CJ involvement makes this a particu-
larly unique and important cohort for addressing key
questions across the HIV treatment cascade.
Methods
Cohort development
The STTR CJ cohort is the product of the STTR Data Col-
lection and Harmonization Initiative developed by the Na-
tional Institute of Allergy and Infectious Diseases (NIAID),
the National Institute on Drug Abuse (NIDA), the National
Institute of Mental Health (NIMH), and the Office of AIDS
Research (OAR). This cohort was developed by a collabor-
ation with researchers who harmonized and pooled data
from independent prospective research studies funded
under a grant mechanism focused on enhancing the STTR
treatment cascade for individuals involved with the CJ sys-
tem across the US [27]. This initiative produced another
cohort not described here focused on vulnerable popula-
tions particularly substance users at risk for or with HIV in
international and domestic settings. While the STTR
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initiative and its rationale have been previously described
[27], the cohort itself has not yet been described.
Cohort management structure
The STTR CJ collaboration consists of a three way partner-
ship between 1) individual researcher teams responsible for
conducting the STTR studies and overseeing all enrollment
and data collection; 2) a scientific officer and program offi-
cials from NIAID, NIDA, NIMH, and OAR who provide
expertise and guidance regarding the data harmonization
initiative; and 3) the STTR Data Coordination Center
(DCC), which provides expertise in data harmonization,
epidemiology, biostatistics, and HIV, harmonizes the data,
supports investigations that use the harmonized data to an-
swer novel scientific questions, and develops new methods
for analysis of complex pooled data.
Cohort description
The STTR CJ cohort is unique in its focus on data from in-
dividuals involved in the CJ system and includes 11 NIAID,
NIDA, NIMH, and OAR funded studies, several of which
involve multiple sub-components and embedded studies. It
includes single and multi-site randomized controlled and
observational trials evaluating interventions to enhance
care delivery along the HIV treatment cascade. It provides
a large sample across CJ settings (jail, prison, community
supervision) and includes both PLWH and HIV-uninfected
individuals, many of whom engage in illicit drug use. Com-
pared to single studies, the CJ cohort data provide in-
creased statistical power to determine public health benefits
of the STTR paradigm, address research questions on spe-
cific groups at risk of exiting the treatment cascade, and im-
prove understanding of the intersection of drug use and
HIV treatment. This cohort profile describes data from the
resulting cohort and individual CJ studies including base-
line demographic and clinical characteristics.
Data harmonization
Eleven domains were selected for data harmonization:
CJ involvement; HIV risk behaviors; HIV and/or hepa-
titis C infection; laboratory measures of CD4+ cell count
and HIV RNA viral load among those with HIV; mental
health; health related quality of life; socioeconomic;
health care access; substance use and alcohol use; and
social support (Fig. 1). The goal is to integrate data from
across studies to address research questions requiring
sample sizes beyond that of a single study.
The DCC, with investigators from individual studies, is
responsible for data integration. The DCC provides tech-
nical support and oversees a web-based project collabor-
ation and document management system; documents
procedures for data collection and translation, transmis-
sion, and quality control; develops integration methods;
and generates analyzable data sets. Studies typically up-
load data biannually. The DCC coordinates data integra-
tion from studies sometimes collected using different
instruments or timeframes to ensure that the data are
comparable across studies in meaning and content. To ac-
complish this, an examination of data types collected by
each study was conducted, working closely with individual
study personnel to survey each study’s protocol including
how data were collected and modifications to the instru-
ments used. Where data were comparable, codes were de-
veloped to create standardized sets of variables.
Availability of data and materials
The datasets generated during the current study are not
publically available due to privacy/license concerns.
Fig. 1 STTR CJ domains selected for data harmonization
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However, we welcome collaboration from interested par-
ties. We have policies to ensure multi-center analytic re-
search proposals are developed and results analyzed
collaboratively and fairly. We are guided by principles of
other cohort collaborations [28–30] including that data at
the DCC will be stripped of all protected health informa-
tion (PHI); an individual study can choose to participate
or not in any scientific aim or sub-aim; and concept pro-
posals and completed manuscripts must be approved by
the Publications and Presentations (P&P) committee. We
appreciate and encourage mentorship and the use of the
STTR data to enable early investigators to address mean-
ingful questions with support to help ensure their success.
Additional information can be obtained at the STTR web-
site: https://sttr-hiv.org/cms or by contacting the STTR
DCC at STTR@uw.edu.
Results
Description of the STTR CJ studies and participants
Figure 2 shows the diverse geography of the participat-
ing studies. For each of the 11 studies and their
substudies, the research topic, the components of the
STTR treatment cascade addressed, and the targeted
participants are described in Table 1. All the steps of the
treatment cascade are included in multiple studies, and
a diverse array of research topics are included. The
STTR CJ cohort includes studies focused on later steps
in the STTR treatment cascade such as treatment and
retention of PLWH and studies focused on earlier steps
such as HIV testing. Therefore, the percentage of PLWH
in the individual STTR CJ studies at baseline varies, ran-
ging from 0 to 100% (Table 1), with an overall baseline
total of 1888 PLWH. For each of the 11 studies and their
substudies, detailed inclusion and exclusion criteria, and
the study design including whether it was observational
or a trial is described in Table 2. In addition to baseline
information, most studies collected data at 3 and/or 6-
month follow-up time points, and many include
12 month and other follow-up time points (Table 2).
The STTR CJ cohort includes 11,070 individuals with
and without HIV who range in age from 18 to 77 years with
a median baseline age of 37 years. The STTR CJ cohort is
Fig. 2 STTR CJ participating sites
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diverse and includes substantial numbers of African-
American (64%) and Hispanic (12%) individuals as well as
17% percent women (Table 3). Given differences in enroll-
ment criteria across STTR CJ cohort studies, the percent-
age reporting HIV risk behaviors varies considerably (Table
4). Injection drug use (IDU) ranged from 86% of partici-
pants reporting ever use in one study, with 64% in that
study reporting IDU within the 30 days prior to incarcer-
ation, to very low levels in other studies (Table 4). Reports
of recent condomless anal or vaginal intercourse also varied
from 4 to 79% of participants. Recent use of marijuana, co-
caine, and opioids, and binge drinking were common
across all studies (Table 5) with 53% reporting use of mul-
tiple substances. Information regarding nonmedical pre-
scriptions drug use is available from 9 of the studies and
substudies. The participants were recruited from a wide
range of CJ settings including jail, prison, and community
supervision (pretrial, parole and probation) with particularly
large numbers of individuals from jail, prison, and proba-
tion (Table 6).
Table 1 Description of STTR CJ cohort studies including research topics, targeted study participants, and HIV status of participants
Study Enrollment start date Treatment cascade Research topic Targeted study participants HIV, %
BRIGHT
BRIGHT 1 2011 S, T HIV testing On probation or parole 0.1
BRIGHT 2 2011 Tr, R Linkage to HIV care via
intensive CM
HIV-infected; on probation
or parole
100
CARE+
RCT 2013 Tr, R Linkage to HIV care via
multi-component intervention
HIV-infected; in jail or recently
released
100
HCV RIDOC 2012 S, T Rapid HCV testing using pre-test
video counseling
Short-term detainees; unknown
HCV status
N/A
HCV PROB 2014 S, T Rapid HCV testing using pre-test
video counseling
On probation or parole; unknown
HCV status
N/A
IMPACT 2012 Tr, R Linkage to HIV care and engagement
in clinical care via multi-component
intervention
HIV-infected inmates; RNA levels
<400 copies/mL, on ART; 3 months
prior to prison release
100
LINK LA 2012 Tr, R Linkage to HIV care via peer-based
intervention
HIV-infected; in jail 100
NEW HOPE 2011 Tr, R Medication assisted treatment for
substance abuse
HIV-infected; opiate dependent;
leaving prison & jail
100
STT 2013 S, T, Tr, R HIV testing and linkage to HIV care Jail detainees 0.4
STT ILLINOIS
OPT OUT 2012 S, T HIV testing In jail N/A
CM JAIL 2013 Tr, R Linkage to, and retention in HIV
care via transition CM
HIV-infected; leaving jail 100
CM PRISON 2013 Tr, R Linkage to, and retention in HIV
care via transition CM
HIV-infected; recently released
from prison
100
START 2011 S, T HIV testing and risk reduction Substance users entering drug
treatment program
N/A
STRIDE
STRIDE 1 2011 Tr, R Medication assisted treatment
for substance abuse
HIV-infected; opiate dependent 100
STRIDE 2 2014 Tr, R Medication assisted treatment for
substance abuse
HIV-infected; opiate dependent 100
SUCCESS 2014 Tr, R Linkage to, and retention in, HIV
care via intensive CM
HIV-infected; jail detainees 100
UHS II
UHS IIC 2011 S, T HIV testing People who inject drugs or smoke
crack cocaine
3.3
UHS IIL 2011 Tr, R Linkage to and engagement in
HIV care via CM
People who inject drugs or smoke
crack cocaine and have HIV
100
ART antiretroviral therapy, CJ criminal justice, CM case management, N/A not applicable, HCV hepatitis C virus, HIV human immunodeficiency virus, R retain, RNA
ribonucleic acid, S seek, STTR seek, test, treat and retain, T test, Tr treat, US United States
Chandler et al. Substance Abuse Treatment, Prevention, and Policy  (2017) 12:24 Page 5 of 13
Table 2 Study design, follow-up, and participant criteria for STTR CJ cohort studies
Studya Study design Follow-up time points Individual inclusion and exclusion criteria
BRIGHT
BRIGHT 1 Randomized/observational
study of on-site rapid HIV
testing at probation/parole
office vs. off-site referral at a
community health center
Baseline only Unknown HIV status; on probation
or parole in Baltimore, MD or
Providence/ Pawtucket, RI and
residence in the Baltimore or
Providence/Pawtucket area
throughout the study period
BRIGHT 2 RCT of case management
(Project Bridge) vs. TAU
3,6,12,15,18 months HIV-infected; on probation or
parole in Baltimore, MD and
planned residence in greater
Baltimore area throughout
the study period
CARE+
RCT RCT of CARE+ Corrections
intervention
Monthly for 24 months Aged 18+; HIV-infected; released
from the correctional facility or
half-way house ≤6 months ago
and living in Washington, DC
metropolitan community
(not a restricted setting, e.g.
half-way house) or currently
detained in jail with anticipated
release to community (not a
restricted setting); reading at 8th
grade level and English-speaking
HCV RIDOC Cross-sectional study of
HCV testing
Baseline only Aged 18+; self-reported as
HCV negative and documented
HCV infection during Department
of Corrections time with anticipated
release between 3 and 12 weeks
from enrollment; English-speaking
HCV PROB Cross-sectional study of
HCV testing
Baseline only Aged 18+; self-reported as HCV
negative or unknown; on probation
or parole; English speaking
IMPACT RCT of IMPACT intervention
vs. standard of care
2, 6, 14, and 24 weeks Aged 18+; HIV-infected with HIV
RNA < 400 copies/mL receiving
ART who were incarcerated in
NC or TX and 3 months prior to
release and not convicted of
sexual assault, death or serious
injury; English-speaking
LINK LA RCT of intervention 2, 6, 12 months Male or transgender individuals,
aged 18+; HIV infected; incarcerated
in a single facility for 5+ days;
residing in Los Angeles County,
CA upon release; English fluency
NEW HOPE Placebo-controlled RCT of.
extended-release naltrexone
Monthly for 12 months Aged 18+, HIV-infected, meeting
DSM-IV criteria for opioid dependence,
within CT corrections system and
not pending trial for a felony, within
30 days of being released to greater
New Haven, Hartford, Waterbury or
Springfield areas or 30 days after
release; English- or Spanish-speaking,
no liver failure or grade IV hepatitis,
no active opioid withdrawal, no
receipt of methadone or
buprenorphine/naloxone for
treatment of opioid dependency,
no participation in pharmacotherapy
trial in the previous 30 days
STT Observational study of comprehensive
Seek Test Treat strategies with
2 years Aged18+; admitted to a detention
facility, expected to be released to
Milwaukee County, WI who were
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Harmonization results
By combining data across multiple studies, we include indi-
viduals involved with varying aspects of the CJ system, enab-
ling comparisons that cannot typically be done within
individual studies. For example, harmonizing data enables
analyses involving subgroups such as transgender individuals
and other subgroups that are often too small to assess in in-
dividual studies.
A key finding from our conduct of data harmonization is
the need for multiple approaches. One technique involved
modern psychometric approaches such as item response
theory (IRT) to co-calibrate scales. Co-calibration enables
Table 2 Study design, follow-up, and participant criteria for STTR CJ cohort studies (Continued)
medical record linkage 2 years
post-release
willing to be tested for HIV; verbal
communication in English
STT ILLINOIS
OPT OUT Cross-sectional study of
opt-out HIV testing
Baseline only Aged 18+; detained in the IL
corrections system
CM JAIL Non-randomized study of
case-management intervention
vs. standard of care
6, 12, 18 months Aged 18+; HIV-infected; detained
in IL corrections system (jail); expecting
to reside in Chicago after release
CM PRISON Non-randomized study of
case-management intervention
vs. standard of care
6, 12, 18 months Aged 18+; HIV-infected; recently
released from IL corrections system
(prison); enrollment was within
60 days of release
START 1. RCT of CARE-Rapid
(computer-assisted program)
vs. TAU and 2. quasi-experimental
study of manualized intervention
vs. TAU, with follow-up at 3 months
3 months Men aged 18+ with either unknown
or believed negative HIV status within
90 days of release from NY detention
center entering a residential substance
abuse treatment program
STRIDE
STRIDE 1 RCT of buprenorphine vs. placebo Monthly for 12 months Aged 18+; HIV-infected; meeting
DSM-IV criteria for opioid dependence;
resident of Washington, DC with eligibility
for medical entitlements; English- or
Spanish-speaking; no current opiate
medications for chronic pain conditions
or need to be placed on such medications;
no current methadone doses over 30 mg/day,
no AST and ALT >5× the ULN; no
pregnancy or breast-feeding; no
liver dysfunction; no suicidal ideation;
no participation in pharmacotherapy
trial in the previous 30 days
STRIDE 2 Longitudinal cohort study comparing
treatment using opioid substitution
therapy to no treatment
3, 6, 9, 12 months Aged 18+; HIV-infected; meeting
DSM-IV criteria for opioid dependence;
resident of Washington, DC with eligibility
for medical entitlements; English-speaking
SUCCESS Non-randomized pilot study of
Strengths-Based case
management and texting
3, 12 months Aged 18+; HIV-infected; detained or
sentenced in jail or detention center
and likely to leave within 6 weeks; no
recent participation in randomized trial
to improve retention in HIV care;
English-speaking
UHS II
UHS IIC Cross-sectional study of HIV testing Baseline only Aged 18+; crack cocaine or injection
drug use in the past 30 days
UHS IIL Longitudinal cohort study of case
management (Project Bridge)
vs. usual treatment
Quarterly for 24 months Aged 18+; HIV-infected; crack cocaine or
injection drug use in the past 30 days
ALT alanine aminotransferase, ART antiretroviral therapy, AST aspartate aminotransferase, CA California, CJ criminal justice, CT Connecticut, DC District of Columbia,
DSM-IV Diagnostic and Statistical Manual of Mental Disorders IV, HCV hepatitis C virus, HIV human immunodeficiency virus, IL Illinois, MD Maryland, NC North
Carolina, NY New York, RCT randomized controlled trial, RI Rhode Island, RNA ribonucleic acid, TAU treatment as usual, TX Texas, ULN upper limit of normal,
WI Wisconsin
aStudy acronyms as in Table 1
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people from studies who responded to different instru-
ments to have scores that are “calibrated together” on a sin-
gle common metric. IRT provides a suite of tools to model
and account for measurement precision. We use this ap-
proach to address differences in the depression and anxiety
measures across studies. In contrast, we found a different
approach was needed to harmonize domains like ART ad-
herence, which are behavioral rather than latent traits.
Below we describe two harmonization efforts for ART ad-
herence and risk behaviors.
Harmonization of ART adherence measures
We used CJ studies that measured ART adherence with
both the AIDS Clinical Trials Group (ACTG) question-
naire and the Visual Analogue Scale (VAS) measure to
develop rules and a formula to co-calibrate both instru-
ments. By co-calibrating adherence items from the
ACTG (7 day recall) with the VAS, we were able to
harmonize studies having different approaches to meas-
uring adherence [31]. We found that 44% of PLWH in
the STTR CJ cohort who were on ART reported
Table 4 Risk behavior characteristics for STTR CJ cohort study participants
Injection drug use, %c Shared injection equipment, %c Condomless sex, %c
Studya Nb Ever
use: yes
Ever use: don’t know,
refused, missing
Recent
use: yes
Recent: don’t know,
refused, missing
Recent
use
Recent use: don’t know,
refused, missing
Recent Recent: don’t know,
refused, missing
BRIGHT
BRIGHT 1
2405 22.4 0.04 4.3 12.3 1.1 12.3 49.9 12.7
BRIGHT 2
100 51.0 10.0 2.0 16.0 1
CARE+
RCT 112 14.3 1.8 4.5 6.3 3.6 5.4 78.6 3.6
HCV
RIDOC
250 17.6 10.0 4.4 −
HCV
PROB
138 13.0 4.4 1.5 −
IMPACT
381 − − − −
LINK
LA
356 − − − 54.8 3.7
NEW
HOPE
123 86.2 3.3 64.2 3.3 17.9 4.9 25.2 3.3
STT 3963 10.5 0.8 6.1 1.2 3.9 0.9 49.1 10.8
STT ILLINOIS
OPT
OUT
236 − 7.6 − −
CM
JAIL
376 − 8.0 0.3 2.7 0.3 28.5 2.7
CM
PRISON
90 − 8.9 1.1 3.3 1.1 38.9 1.1
START 195 − 3.6 − 25.1 0.5
STRIDE
STRIDE
1
50 76.0 4.0 34.0 4.0 4.0 8.0 4.0 6.0
STRIDE
2
109 49.5 15.6 3.7 0.9 17.4 6.4
SUCCESS
56 − 10.7 − 51.8 3.6
UHS II
UHS
IIC
2090 43.0 26.5 − 64.5 0.05
UHS
IIL
48 37.5 22.9 52.1
CJ criminal justice, STTR seek, test, treat and retain
aStudy acronyms as in Table 1
bThere are 33 participants who are included in more than one sub-study: 3 in BRIGHT 1 and BRIGHT 2, and 30 in UHSIIC and UHSIIL
cReference periods differed across studies; 30 days: STRIDE 1, NEWHOPE, START, SUCCESS, 90 days: BRIGHT 1 and 2, STRIDE 2, all STT Illinois studies, CARE + HCV
RIDOC, CARE + RCT, STT, 180 days: LINK LA, UHS II. The following studies measured pre-incarceration risk behaviors: CARE+ RCT, CARE+ HCV RIDOC, LINK LA, NEW
HOPE, STT, STT ILLINOIS OPT OUT, STT ILLINOIS CM JAIL, and STT ILLINOIS CM PRISON
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adherence rates <95% for the prior 30 days and 38% re-
ported having missed one or more doses in the prior
14 days. Furthermore, we found important variations
not only in ART adherence in different groups, but also
in how adherence measures work. The findings also
highlighted problems with the VAS as a single item ad-
herence measure and showed its validity varied across
groups. These results would not have been feasible
within single studies but instead were possible by har-
monizing multiple studies to gain both necessary sample
size and variation [32].
HIV sexual risk behavior harmonization
Eight studies administered a standardized risk behavior
assessment tool to evaluate sexual risk behaviors in these
reference periods: 30 or 90 days prior to incarceration
for jail and prison detainees, or the previous 30 or
90 days for participants enrolled in the community. We
described sexual risk behaviors of HIV-infected and un-
infected participants in these studies and compared men
and women [33, 34]. To test for differences in risk be-
haviors between men and women, we performed individ-
ual patient data meta-analysis to combine information
across studies. Findings indicated a high prevalence of
condomless anal or vaginal sex among PLWH and unin-
fected participants, particularly women with HIV. For
example, the adjusted odds ratio for condomless sex was
1.84 (1.16-2.95) for women with HIV compared with
men with HIV [34]. By aggregating data across studies,
we were able to overcome the much lower prevalence of
women in CJ populations and, in turn, in each of the in-
dividual CJ studies.
Table 5 Substance use distribution for STTR CJ study participants
Alcohol use, %c,e Substance use, %d,e Multiple substance use, %d,e
Studya Nb Any Binge Marijuana Cocaine Opioids Stimulants Other ≥2 substances (including alcohol)
BRIGHT
BRIGHT 1 2405 48.2 28.7 27.5 10.7 13.0 0.3 2.9 29.9
BRIGHT 2 100 44.0 25.0 22.0 26.0 23.0 1.0 3.0 38.0
CARE+
RCT 112 80.4 60.7 35.7 37.5 17.0 8.9 20.5 54.5
HCV RIDOC 250 71.6 60.4 60.8 24.8 31.2 9.2 22.0 66.8
HCV PROB 138 63.8 37.0 42.0 15.9 10.9 2.9 4.4 39.1
IMPACT − − − − − − − − −
LINK LA 356 53.1 24.7 54.2 17.1 10.1 58.1 9.8 66.3
NEW HOPE 123 37.4 22.8 23.6 77.2 91.9 0.8 8.9 81.3
STT 3963 46.5 31.4 37.7 14.8 13.8 9.8 14.4 38.9
STT ILLINOIS
OPT OUT − − − − − − − − −
CM JAIL 376 71.0 49.5 45.0 39.1 32.5 14.1 10.4 65.7
CM PRISON 90 75.6 53.3 63.3 44.4 41.1 13.3 13.3 77.8
START 195 72.8 53.9 35.9 21.5 21.0 1.0 12.3 47.2
STRIDE
STRIDE 1 50 58.0 22.0 6.0 24.0 92.0 0.0 6.0 58.0
STRIDE 2 109 62.4 33.0 24.8 41.3 83.5 6.4 11.0 69.7
SUCCESS 56 71.4 48.2 51.8 48.2 25.0 21.4 1.8 57.1
UHS II
UHS IIC 2090 79.7 54.6 61.7 90.8 47.3 10.6 12.0 92.3
UHS IIL 48 64.6 39.6 66.7 66.7 22.9 6.3 8.3 72.9
CJ criminal justice, STTR seek, test, treat and retain
aStudy acronyms as in Table 1
bThere are 33 participants who are included in more than one study: 3 in BRIGHT 1 and BRIGHT 2, and 30 in UHSIIC and UHSIIL
cAlcohol reference periods differed across studies; 30 days: LINK LA, NEW HOPE, START; UHS II; 90 days: BRIGHT 1 and 2, STT; 180 days: STT Illinois; 1 year:
CARE + RCT, SUCCESS; not specified: STRIDE 1 and 2, START
dSubstance reference periods differed across studies; 30 days: LINK LA, NEW HOPE, START Together; STRIDE 1, SUCCESS, UHS II; 90 days: BRIGHT 1 and 2, CARE+
RCT and HCV RIDOC, STT Strategies, STRIDE 2; 180 days: STT Illinois
eThe following studies measured pre-incarceration alcohol and substance use: CARE+ RCT, CARE+ RIDOC, LINK LA, NEW HOPE, STT, STT JAIL, STT PRISON,
and SUCCESS
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Discussion
STTR CJ is a unique cohort that combines data from 11
studies that together address steps across the HIV treat-
ment cascade focusing on participants with CJ involve-
ment. The STTR CJ cohort includes a large and diverse
assemblage of individuals who are at risk for, or living with
HIV. The pooled data cohort is a sample of men, women,
and transgender individuals across different racial/ethnic
groups in multiple CJ settings (prison, jail, pre-trial, com-
munity supervision) as well as participants with no CJ in-
volvement. The intervention studies span the HIV
treatment cascade and have broad geographic locations
across the US with participants enrolled from 11 states
and the District of Columbia. These characteristics pro-
vide the opportunity to address questions of great import-
ance for HIV prevention and treatment particularly
related to individuals involved in the CJ system, those at
risk or with HIV and using substances, and the unique
risks and clinical needs of specific subgroups. For ex-
ample, we are particularly interested in understanding the
impact of changes in the intensity of substance use on
HIV care cascade outcomes such as viral suppression and
adherence, the impact of incarceration and release on the
HIV care continuum, and to better understand risk behav-
iors of individuals upon release from incarceration. Finally,
the study investigators and DCC have expertise in clinical,
epidemiologic, CJ, biostatistical, and data harmonization
areas. This team is well-positioned to address trans-
disciplinary scientific questions and identify new questions
that will arise as HIV care and prevention continues to
evolve, and we have developed harmonized measures to
allow for combining studies to answer these questions.
There are limitations to the STTR CJ cohort data.
Some of these limitations are inherent in combining data
from independent studies with different enrollment cri-
teria and different study designs. While the STTR CJ co-
hort includes a large number of CJ-involved PLWH or
persons at risk of HIV, this combination of studies is not
a representative sample of those involved in the CJ sys-
tem in the US, and in particular may underrepresent
Table 6 Supervision status for STTR CJ cohort study participants
CJ supervision status, %
Studya Nb No current CJ supervision Jail Prison Probation Parole Probation/parole Other Don’t know, refused, missing
BRIGHT
BRIGHT 1 2405 0 0 0 81.3 15.2 3.5 0 0.08
BRIGHT 2 100 0 0 0 69.0 25.0 6.0 0 0
CARE+
RCT − − − − − − − − −
HCV RIDOC 250 0 0 100 0 0 0 0 0
HCV PROB 138 0 0 0 97.8 0.7 0.7 0 0.7
IMPACT 381 0 0 100 0 0 0 0 0
LINK LA 356 0 100 0 0 0 0 0 0
NEW HOPE 123 0.0 58.5 27.6 3.3 0.8 0.0 5.7 4.1
STT 3963 0 100 0 0 0 0 0 0
STT ILLINOIS
OPT OUT 236 0 100 0 0 0 0 0 0
CM JAIL 376 0 100 0 0 0 0 0 0
CM PRISON 90 14.4 0.0 0.0 0.0 78.9 4.4 1.1 1.1
START − − − − − − − − −
STRIDE
STRIDE 1 50 44.0 0.0 0.0 16.0 30.0 4.0 4.0 2.0
STRIDE 2 109 78.9 0.0 0.0 3.7 10.1 0.0 6.4 0.9
SUCCESS 56 0 100 0 0 0 0 0 0
UHS II
UHS IIC 2090 68.0 0 0 23.5 6.1 2.1 0 0.2
UHS IIL 48 52.1 0 0 35.4 4.2 8.3 0 0
CJ criminal justice, STTR seek, test, treat and retain
aStudy acronyms as in Table 1.
bThere are 33 participants who are included in more than one study: 3 in BRIGHT 1 and BRIGHT 2, and 30 in UHSIIC and UHSIIL
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rural areas. Harmonization of some variables has been
difficult due to modifications made by some individual
studies to standardized instruments and data collection
timeframes. For example, some studies modified time-
frames for behaviors that were assessed (30 days vs.
90 days) to fit their study follow-up periods. Missing
data varied by participating study and some studies have
limited or no data on certain domains. This means that
it is not feasible to use all studies in some analyses. For
example, studies varied in whether they focused on
current substance use or included type of substances at
the time of incarceration. HIV status also varied with
studies focused on later stages in the HIV cascade more
likely focusing on PLWH. Similarly, studies that focused
on late stages of the cascade cannot contribute to HIV
risk analyses in that all participants are PLWH. The het-
erogeneity of study designs in the participating studies
including both observational and interventional studies
makes it feasible to study all the different stages of the
STTR cascade but also complicates approaches to com-
bining studies. When merging these studies it is critical
to identify the subset of the STTR CJ cohort appropriate
for and able to provide data on the research questions of
interest. These studies recruited from diverse source
populations. For example, two studies recruited partici-
pants who were at high risk of CJ system involvement
but not necessarily already involved with the CJ system
at baseline. This variation prevents the naïve pooling of
studies, as baseline characteristics are different between
studies, and requires clustering of participants by study
be accounted for using a mixed model or generalized es-
timating equation approach. Longitudinal follow-up dur-
ation and frequency varies with several studies having
limited follow-up time although we will continue to in-
clude all additional data collected over follow-up, so
long as studies remain ongoing. While this variation
limits power for analyses looking at longitudinal out-
comes, the STTR CJ cohort remains better powered
than individual studies.
The STTR CJ cohort is designed to allow expansion
for new studies and domains as needed to address im-
portant questions in the HIV research agenda particu-
larly related to the STTR treatment cascade. New
studies will be added as needed to increase demographic,
geographic, or clinical diversity and broaden scientific
expertise. The STTR CJ cohort welcomes collaboration
from interested parties and has policies to ensure multi-
center analytic research proposals are developed and re-
sults analyzed collaboratively and fairly.
Conclusions
This cohort provides a large study sample across differ-
ent CJ settings (jail, prison, community supervision) and
includes both persons with and without HIV, many of
whom engage in illicit drug use. Compared to single
studies, the combined data of the CJ cohort provides in-
creased statistical power to determine the public health
benefit of the STTR paradigm, address research ques-
tions on specific groups at risk of exiting the treatment
cascade, and improve understanding of the intersection
of drug use and HIV treatment.
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